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Interleukin-1beta-induced reduction of
tissue water diffusion in the juvenile rat
brain on ADC MRI is not associated with
31P MRS-detectable energy failure
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Abstract
Background: It has long been known that an intrastriatal microinjection of the archetypal pro-inflammatory cytokine,
interleukin-1beta (IL-1β), in juvenile rats induces a chronic reduction in the apparent diffusion coefficient (ADC) of tissue
water on magnetic resonance imaging (MRI). Reduced ADC during acute cerebral ischaemia is an established indicator
of metabolic failure whereas the cause of the IL-1β-induced reduction remains to be deciphered. Previously, it has
been shown that IL-1β does not perturb the phosphorus (31P) magnetic resonance spectroscopy (MRS)-detectable
energy status of an ex vivo preparation of rat brain parenchyma that is devoid of a functional vasculature component.
However, brain energy status following an IL-1β challenge in vivo remains to be examined.
Methods: This study is the first longitudinal in vivo examination of the correlation of ADC MRI with localised 31P MRS
signals obtained specifically from within the injected and non-injected striatum following IL-1β (1 ng/ul or 100 ng/ul)
challenge, in real-time.
Results: Despite observing a chronic reduction in ADC at either dose of IL-1β challenge, energy compromise was not
detected at any time point.
Conclusions: The IL-1β-induced effects pertaining to a functional vasculature such as leukocyte recruitment, blood–
brain barrier (BBB) breakdown and blood flow changes are unlikely to impact on overall tissue energy status. Compared
to classic ischaemia, there is dissociation between ADC and energy status within an IL-1β-induced lesion in vivo.
Keywords: Interleukin-1beta, Magnetic resonance imaging, Apparent diffusion coefficient, Phosphorus magnetic
resonance spectroscopy, Energy metabolism, Brain
Background
Evidence suggests that the archetypal pro-inflammatory
cytokine, interleukin-1beta (IL-1β), is a key component
in the pathogenesis of stroke, Alzheimer’s disease (AD)
[for review, see 1] and Parkinson’s Disease (PD) [for re-
view, see 2]. These are complex pathologies in which it
can be difficult to determine the physiological actions of
IL-1β in the brain. However, by examining the conse-
quences of a cerebral IL-1β challenge we may facilitate
our understanding of the role of this cytokine in neuro-
degenerative disease and disorder.
Intrastriatal microinjection of IL-1β in three-week-old
(P21) juvenile rats induces a chronic reduction in the ap-
parent diffusion coefficient (ADC) of tissue water on
magnetic resonance imaging (MRI) [3]. This is indicative
of a loss of high-energy phosphates, detectable using
non-invasive phosphorus (31P) magnetic resonance spec-
troscopy (MRS), in experimental acute cerebral ischae-
mia [4–6]. Mechanistically, a reduction in cerebral blood
flow (CBF) promotes the failure of adenosine triphos-
phate (ATP)-dependent cell membrane ion pumps, dys-
regulating cell volume [for review, see [7], inducing cell
swelling, reducing the extracellular space and, therefore,
the ADC [8–10].Correspondence: raman.saggu@wolfson.oxon.org
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Contrary to classic ischaemia where ADC changes
occur swiftly within a matter of minutes [11], IL-1β-
induced changes do not present until 6 h post challenge
[3]. Furthermore, IL-1β increases regional cerebral blood
volume (rCBV), lactate levels remain unaltered [3], and
there is an absence of neuronal cell death [12, 13]. It has
been suggested that IL-1β-induced neutrophil-mediated
blood-brain-barrier (BBB) breakdown may influence
water diffusion within the rat brain parenchyma, affect-
ing ADC changes [3]. However, BBB breakdown occurs
between 4 h and 5 h and gadolinium post-contrast en-
hancement diminishes by 6 h when ADC first becomes
significantly reduced [3]. Furthermore, the BBB reseals
itself by 24 h whereas ADC changes persist up to 123 h,
and are not prevented by neutrophil depletion [3]. IL-
1β-induced morphological changes such as microglial
activation or cell swelling have also been suggested as
possible explanations for the reduced ADC [12]. Elec-
trical impedence measurements in a rat model of
NMDA-induced excitotoxic injury have shown that an
~10 % cell swelling corresponds to an ~50 % reduction
in ADC [10]. However, microglia revert to resting
morphology 72 h post IL-1β challenge whilst ADC re-
mains depressed beyond this time point [3]. Thus, al-
though ischaemia, BBB changes and cell swelling do not
seem to account for the ADC reduction observed in this
model, IL-1β-induced energy failure in vivo remains a
possibility.
Reduced ADC is observed in rat models of N-methyl-D-
aspartate (NMDA)- [14] or ouabain-induced [15] excito-
toxic injury, and bicuculline-induced status epilepticus
[16], which exhibit no apparent ischaemic component to
their pathology. Nevertheless, these studies sought to cor-
relate ADC changes with the energy status of the brain
given the strong association between failure of energy-
dependent transmembrane Na+/K+-ATPase ion pumps
and dysregulation of cell volume [for review, see 7].
Therefore, the metabolic status of brain parenchyma fol-
lowing IL-1β challenge in vivo warrants examination to
determine whether an ischaemia-independent energy def-
icit may be associated with the reduction in ADC.
IL-1β does not appear to affect high-energy phosphate
metabolism of an ex vivo preparation of brain parenchyma
per se [17]. 31P MRS was used to characterise the energy
status of organotypic hippocampal-slice cultures (OHSCs)
prior to and following IL-1β challenge. The OHSC set-up
preserves brain parenchyma cytoarchitecture and synaptic
connectivity without the complication of a functional vas-
cular component. Thus, the vascular-related consequences
of an IL-1β challenge in vivo such as neutrophil recruit-
ment, blood–brain barrier (BBB) and perfusion changes [3]
can be extricated from those pertaining to the parenchyma.
The question of whether IL-1β affects cerebral energy
metabolism remains partly addressed; tissue energy
status should additionally be addressed in vivo where the
physiological consequences of a functional vasculature
are included. Furthermore, the classic bio-imaging
marker of an energy deficit - a reduced ADC - may only
be observed, followed and correlated with metabolism in
real-time, in vivo.
Herein, the energetic contribution to the IL-1β-induced
reduction in ADC in vivo was examined. A comprehen-
sive characterisation of the real-time longitudinal evolu-
tion of the lesion on ADC MRI is presented. Localised 31P
MRS-detectable energy status, as determined by the
phosphocreatine (PCr) to ATP ratio [18], was measured
within the ipsilateral and contralateral striatum 6 h follow-
ing intrastriatal microinjection of 1 ng/μl IL-1β when
ADC first becomes reduced at this dose [3]. Additionally,
31P MRS, ADC and anatomical [T1-weighted (T1-w)/T2-
weighted (T2-w)] MRI data were acquired serially in the
same animal at 2.5 h, 6 h, 24 h and 72 h following an
intrastriatal 100 ng/μl IL-1β challenge.
Methods
Reagents
Rat recombinant (rr) cytokine, interleukin-1beta (rrIL-1β)
(NIBSC, Potters Bar, UK) was dissolved in endotoxin-free
saline (vehicle).
Animal preparation
Three-week-old male juvenile Wistar rats (Harlan-Olac)
were used to examine the effects of an intrastriatal IL-1β
challenge, as reported previously [3]. Animals were
anaesthetised by inhalation using 2.0 % isoflurane in
70 % N2O: 30 % O2 and positioned within a stereotaxic
frame. Under microscope guidance, a burr hole was
made in the skull 3 mm caudal and 1 mm lateral to
Bregma in the left hemisphere. Using a finely drawn
glass micropipette, 1 μl injection of the IL-1β solution
(1 ng/μl or 100 ng/μl) was delivered at a depth of 4 mm
from the brain surface over a 5 min period. Control ani-
mals were injected with saline. Animals were placed in a
purpose-built head restraint system comprised of a tooth
bar and a nose strap integral to the coil. A 2 cm-diam-
eter, single-turn, 31P-tuned (32.5 MHz) circular surface
coil, bent to conform to the curve of the skull, was posi-
tioned over the animal’s head and used for both excita-
tion and signal acquisition. Anaesthesia was maintained
within the magnet using 1.0 % isoflurane in 70 % N2O:
30 % O2 administered via tubing positioned around the
animal’s snout. All procedures were carried out with eth-
ical approval under a UK Home Office Licence.
Magnetic resonance methods
MR measurements were made using a 300 MHz (7 Tesla)
horizontal bore magnet (Oxford Instruments, Oxford,
UK), internal bore size 10.2 cm. Data acquisition, gradient
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and waveform generation, and ancillary processes were
carried out on a Varian Inova System spectrometer
(Varian Medical Systems, Palo Alto, CA, USA).
Proton MR Probe
Radiofrequency (RF) pulses were applied using a 3.4 cm
Alderman-Grant resonator (4.2 cm in length) secured in-
side an custom-built cylindrical Perspex probe body
(34 cm in length; aluminium base plate: 21 cm in length).
The internal dimensions of the coil closely matched the
size of the animal’s head, thereby minimising noise acqui-
sition from areas other than the region of interest. An
earthed copper shield was positioned around the RF coil
to prevent coupling between the probe and gradients. The
RF coil was part of a tunable resonance circuit.
Anatomical imaging
Anatomical (T1-weighted and T2-weighted/T1-w and T2-w)
images were acquired using a fast spin-echo sequence.
T1-w images used a repetition time (TR) of 0.5 s, and an
echo time (TE) of 0.02 s whereas T2-w images used a TR
of 3.0 s and a TE of 0.04 s. Slice thickness, 1 mm; field of
view (FOV), 3 × 3 cm2; matrix size, 128 × 128 pixels with
nominal in-plane resolution, 0.23 × 0.23 mm2.
Diffusion-weighted imaging
Diffusion-weighted images (DWI) were acquired using a
navigated pulsed-gradient spin-echo sequence with a TR
of 2 s and a TE of 0.0365 s. Imaging was performed
using the three diffusion-weighting (“b”) values of 125,
500 and 1000 s/mm2, where b is defined by the equation
b = (γGδ)2[Δ − δ/3] [19]. G is the diffusion gradient
strength; Δ, the diffusion time, was 17.5 ms and δ, the
diffusion gradient duration, was 12.5 ms. Diffusion gra-
dients were applied simultaneously on all three axes,
and “trace” diffusion measurements were calculated [20].
Motion correction was addressed using navigator echoes
[21]. Slice thickness, 1 mm; FOV, 3.5 × 3.5 cm2 and
matrix size, 128 × 128 pixels.
Phosphorus magnetic resonance spectroscopy
Localised phosphorus MR spectra were acquired from a
cuboidal volume (5 × 6 × 4 mm3) positioned within the
striatum of each hemisphere. An image-selected in vivo
spectroscopy (ISIS) sequence was used to minimise signal
contamination from other brain regions (TR, 6 s; transient
number, 600; TE, 0.01 s; number of points, 6144; total
acquisition time, 1 h 56 s; bandwidth, 6000 Hz). Proton
decoupling was applied.
Experimental protocol
Each animal was injected with IL-1β or vehicle at time 0
and serially imaged 2.5 h, 6 h, 24 h and 72 h post chal-
lenge. Animals were allowed to recover after the 6 h, 24 h
and 72 h time points. T2-w, T1-w, ADC MRI and
31P
MRS data were acquired for each animal and the time
point for each image was taken to be the mid-point of the
image acquisition time. 31P MRS data for the contralateral
hemisphere at 6 h was not obtained as this would have
prolonged the extensive (10 h) protocol on day 1 of im-
aging by a further 1.5 h. Maintaining the animal under an-
aesthesia for long periods risks death and changes in
energy metabolism were not expected to be observed in
the contralateral hemisphere at this time point.
MRI: vehicle-injected animals, n = 3 at each time point;
100 ng/μl IL-1β-injected animals, n = 6 at each time
point. 31P MRS: vehicle-injected animals, n = 3 at each
time point; 100 ng/μl IL-1β-injected animals, n = 6 at
2.5 h, n = 5 at 6 h, n = 6 at 24 h, n = 4 at 72 h ipsilateral
hemisphere and n = 5 at 2.5 h, n = 4 at 24 h, n = 5 at
72 h contralateral hemisphere; 1 ng/μl IL-1β-injected an-
imals, n = 4 at each time point.
Magnetic resonance data analysis
ADC MRI
Quantitation of ADC perturbation ADC images were
generated from diffusion-weighted images [22]. Reduc-
tion in ADC was quantified by: 1) Drawing a region of
interest (ROI) onto ADC maps, using a freehand cursor,
that encompassed the striatum of the contralateral hemi-
sphere of each animal at each time point, and attaining
an average value for the SD of the ADC. 2) Thresholding
each ADC map by subtracting 1 times the average SD
from the actual ADC value of each animal at each time
point. Previously, Blamire and colleagues reported
thresholding ADC maps to 1 SD below the mean for
analysis following intrastriatal microinjection of 1 ng/μl
IL-1β [3]. 3) Drawing an ROI around the areas highlighted
by thresholding within the injected hemisphere. 4) Map-
ping the ROI back onto original ADC maps to attain the
ADC value, which also gives the ROI area. 5) Flipping the
ROI of the injected hemisphere on the original ADC map
onto the contralateral hemisphere to attain an ADC value
for the non-injected hemisphere.
Measuring ADC within an ROI encompassing the
dimensions of the 31P MRS voxel In addition to draw-
ing an ROI around the area highlighted by thresholding
and mapping back onto original ADC maps, separate
ADC values were obtained for the ROI encompassing
the dimensions of the 31P MRS voxel within the striatum
of the ipsilateral and contralateral hemispheres.
31P MRS Spectra were fitted in the time domain using a
nonlinear least squares algorithm (AMARES) [23, 24].
The phosphocreatine (PCr) to gamma (γ) adenosine tri-
phosphate (ATP) ratio was used as a measure of tissue
energy status [18].
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Statistics
Statistical analysis was performed using student t-test or
repeated measures analysis of variance (ANOVA) test.
Results
MRI
Thresholding demonstrates a significantly reduced ADC that
presents at 6 h and persists up to 72 h
One-way ANOVA showed significant variation in ADC
of the IL-1β-injected hemisphere (p = 0.0004), and post-
testing using Bonferroni multiple comparisons test
showed a significantly reduced ADC at 6 h (p < 0.01),
24 h (p < 0.001) and 72 h (p < 0.01) compared with 2.5 h
(Fig. 1a and b).
The area of reduced ADC, identified by thresholding, is
spatially greatest at 24 h
One-way ANOVA showed significant variation in the area
of reduced ADC from 6 h to 72 h (p = 0.0063), and post-
testing using Bonferroni multiple comparisons test showed
a significantly greater area at 24 h compared with 6 h (p <
0.05) (Fig. 1c).
With respect to the dimensions of the 31P MRS voxel, the
ADC change is significant at 24 h only, and returns to
baseline by 72 h
One-way ANOVA showed significant variation (p =
0.0034) in the ADC of tissue contained within the 31P
MRS voxel. Post-testing using Bonferroni multiple com-
parisons test showed significantly reduced ADC at 24 h
compared with 2.5 h (p < 0.01) (Fig. 1d). By 72 h, there
was no significant difference in ADC between the IL-1β-
and vehicle-injected hemispheres (p = 0.6151; unpaired t-
test).
The ADC of the ROI at 6 h (ROI6 h) remains persistently
depressed throughout the course of the study
One-way ANOVA showed significant variation in the ADC
of ROI6 h, p = 0.0416, although post-testing by Bonferroni




Fig. 1 Time course of MRI changes following intrastriatal microinjection of 100 ng/μl IL-1β. a Representative T2-w and T1-w images, ADC maps and
their respective thresholded images from the same animal (1 SD below mean ADC of contralateral hemisphere of cohort imaged at 2.5 h, 6 h, 24 h
and 72 h). Arrow points to injection site, visible as a focal area of T2-w hyperintensity at 2.5 h and 6 h, and reflects the volume of fluid injected.
b ADC changes determined by thresholding. Mean ADC (error bars indicate a 1 SD) within the ipsilateral or contralateral striatum. Statistical significance
indicated by *** p < 0.001, * p < 0.05; paired t-test, † p < 0.05; unpaired t-test and▲▲▲ p < 0.001,▲▲ p < 0.01; one-way ANOVA, post-testing using
Bonferroni multiple comparisons test, with respect to the ADC of the IL-1β-injected hemisphere at 2.5 h c Evolution of area of reduced ADC. Mean area
(error bars indicate a 1 SD) within the injected hemisphere. Statistical significance indicated by▲ p < 0.05; one-way ANOVA, post-testing using
Bonferroni multiple comparisons test, with respect to the area of reduced ADC at 6 h. d ADC measured within the dimensions of the 31P MRS voxel
(position and dimensions shown in Fig. 1a). Mean ADC (error bars indicate a 1 SD) within a region of interest encompassing the 31P MRS voxel within
the ipsilateral or contralateral striatum. Statistical significance indicated by * p < 0.05; paired t-test▲▲ p < 0.01; one-way ANOVA, post-testing using
Bonferroni multiple comparisons test, with respect to the ADC of the IL-1β- injected hemisphere at 2.5 h. Vehicle- (saline) injected animals (n = 3 at
each time point) and IL-1β-injected animals (n = 6 at each time point)
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of reduced ADC at 6 h remains depressed throughout the
course of the study (Fig. 2a and b).
The ADC of the spatial difference between the initial ROI
(ROI6 h) and the ROI of greatest spatial extent at 24 h
(ROI24 h) decreases further between 6 h and 24 h
The ADC of the spatial difference between the 6 h and
24 h ROI (ROI6 h-24 h) became further reduced at 24 h
compared with 6 h as demonstrated by one-way ANOVA,
p = 0.0154 and post-testing using Bonferroni multiple
comparisons test (Figs. 2a and c).
31P MRS
31P MR spectra exhibited the prime high-energy phos-
phates: the phosphomonoesters, PME; inorganic phosphate,
Pi; phosphocreatine, PCr and adenosine triphosphate, ATP.
ATP comprises three resonances, one arising from each of
the phosphorus atoms in the ATP molecule: gamma (γ),
alpha (α) and beta (β)ATP (Fig. 3). Each resonance is a
multiplet determined by the number of neighbouring phos-
phorus nuclei influencing the magnetic field of each 31P nu-
cleus: βATP being a triplet and the γATP and αATP
resonances doublets. Spectra were centred (transmission
off-resonance, tof) halfway between the PCr and γATP res-
onances to enable optimal resolution of these peaks, which
are required for calculating the energy status (PCr to γATP
ratio); hence the relatively poor phasing of the PME,
Pi and βATP peaks.
Intrastriatal microinjection of 1 ng/μl IL-1β induces a reduction
in ADC at 6 h that is not accompanied by a 31P MRS-detectable
reduction in the PCr to γATP ratio
There was no difference in the mean PCr to γATP ratio
(Fig. 4a) of the IL-1β-injected ipsilateral and contralat-
eral hemispheres at 6 h (p = 0.7890, n = 4, paired t-test),
or in the mean PCr to γATP ratio of the IL-1β- and
vehicle-injected ipsilateral hemispheres at 6 h (p =
0.3243, n = 3, unpaired t-test).
Intrastriatal microinjection of 100 ng/μl IL-1β induces a
chronic reduction in ADC that is not associated with a
perturbation in the PCr to γATP ratio at any time point
(2.5 h, 6 h, 24 h or 72 h)
There was no significant variation in the PCr to γATP
ratio of the IL-1β-injected ipsilateral (one-way
ANOVA, p = 0.4824) or contralateral hemisphere (one-way
ANOVA, p = 0.2526). Paired t-test showed no significant
difference in the PCr to γATP ratio of the IL-1β-injected ip-
silateral and contralateral hemispheres at 2.5 h (p = 0.3434),
24 h (p = 0.6347) or 72 h (p = 0.6434) (Fig. 4b).
Power calculations
Power analysis for the PCr to γATP ratio of the IL-
1β-injected ipsilateral versus contralateral hemisphere,
paired t-test at 24 h was performed according to
Rosner (2011) [25]. This gave a sample estimate of
n = 49 in each group (injected and contralateral
hemisphere) needed to observe a change in the




Fig. 2 ADC ROI mapping. a The ROI of reduced ADC, identified by
thresholding, when it first becomes reduced (ROI6 h) was mapped
forwards onto original ADC maps at subsequent time points (in white).
The ROI of reduced ADC at 24 h (ROI24 h), the greatest area of ADC
change, was mapped onto 6 h and 72 h ADC maps (in black). The ROIs
of 6 h and 24 h time points are overlaid in the last row; the spatial
difference representing the ADC of ROI6 h-24 h. All images are from the
same animal and are representative of the group. b Time course of
development of the ADC of the ROI6 h. Mean ADC (error bars indicate a
1 SD). c Time course of development of the ROI6 h-24 h. Mean ADC (error
bars indicate a 1 SD). Statistical significance indicated by▲ p< 0.05;
one-way ANOVA, post-testing using Bonferroni multiple comparisons
test, with respect to the ADC at 6 h. IL-1β-injected animals, n= 6 at each
time point
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(α) = 0.05, type II error (β) = 20 %. The equations
applied were:
σd
2 ¼ σ22 þ σ122ρσ1σ2 where : ð1Þ
ρ = Pearson correlation coefficient;
σ1 = standard deviation for the contralateral hemisphere
at 24 h;
σ2 = standard deviation for the injected hemisphere at
24 h;
n ¼ 2σd




μ1 =mean value of the contralateral hemisphere at 24 h;
μ2 = mean value of the injected hemisphere at 24 h;
zq = q
th percentile of a normal distribution.
Vehicle imaging changes
T1-w imaging did not detect any effects of IL-1β or ve-
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Fig. 3 Representative in vivo 31P MR spectra from a the ipsilateral striatum of a 1 ng/μl IL-1β-injected animal, b the ipsilateral striatum of a
100 ng/μl IL-1β-injected animal and c the contralateral striatum of a 100 ng/μl IL-1β-injected animal. Each spectrum exhibits peaks from the
phosphomonoesters (PME, a); inorganic phosphate (Pi, b); the phosphodiesters (PDE, c); phosphocreatine (PCr, d) and the three resonances of
the gamma (γ, e), alpha (α, f) and beta (β, g) phosphates of adenosine triphosphate (ATP). d Representative 31P MR spectrum of the ipsilateral
striatum of a saline-injected animal showing integration of the spectral peaks. (i) Original spectrum. (ii) Baseline correction and spectral fit using a
software package compiling the AMARES algorithm [23, 24]. (iii) γATP and αATP are doublets and comprised of two resonances of equal area, γ:
peaks 5 and 6, α: peaks 7 and 8 respectively. βATP is a triplet comprised of three resonances; two of which are of equal area: peaks 9,10 and 11.
PCr (peak 1) is a singlet. (iv) The spectral residue (spectrum minus fit).
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visible on T2-w imaging 2.5 h following either IL-1β or
vehicle microinjection, which resolved thereafter, and is
likely due to the volume of fluid injected. Vehicle-
injected animals exhibited elevated ipsilateral ADC com-
pared with the contralateral hemisphere at 2.5 h, due to
the volume of saline injected, which transiently raises
the ADC. 31P MRS of vehicle-injected animals demon-
strated no change in energy status at any time point.
Discussion
In the present study, the energetic contribution to the
IL-1β-induced reduction in ADC was examined in vivo,
for the first time. A potential energy deficit was hypothe-
sised since failure of the ATP-dependent transmembrane
ion pumps [for review, see 7] is critical in controlling
the volume of the intra- and extracellular space, and
thus the ADC [8–10].
An IL-1β-induced (100 ng/μl) reduction in ADC was
observed from 6 h to 72 h post challenge (as determined
by thresholding), and was due to a combination of the
ADC of the initial ROI at 6 h (ROI6 h) remaining de-
pressed throughout the study (Fig. 2b) and the ADC of
the spatial difference between ROI 6 h and ROI 24 h
(ROI6 h-24 h) becoming further depressed (Fig. 2c). How-
ever, the ADC within the dimensions of the 31P MRS
voxel was reduced only at 24 h (Fig. 1d), coinciding with
the greatest spatial extent of ADC change (Fig. 1c), and
returned to baseline by 72 h (Fig. 1d). The difference in
sensitivity with respect to both analyses is important, as
the ADC changes detected by thresholding are spatially
smaller than the dimensions of the 31P MRS voxel
(Fig. 1a). If an IL-1β-induced reduction in ADC is in-
deed associated with energy failure, the spatial extent of
ADC changes at 6 h and 72 h may not be sufficient to
correlate with 31P MRS-detectable perturbations in the
PCr to γATP ratio. However, the large spatial extent of
ADC change at 24 h (Fig. 1a and c) in parallel with a sig-
nificantly reduced ADC (Fig. 1b and d) suggests that one
should, at least, be able to detect energy failure at this
time point.
Interestingly, 31P MRS did not detect a change in the
PCr to γATP ratio at any time point following 100 ng/μl
IL-1β challenge (Fig. 4b), nor at 6 h following 1 ng/μl
IL-1β challenge (Fig. 4a) when ADC is first reported to
become reduced at this dose [3]. This finding is in agree-
ment with previous observations using an ex vivo prep-
aration of rat brain parenchyma that demonstrated an
unperturbed 31P MRS-detectable energy status 6 h fol-
lowing incubation with IL-1β [17].
In vivo localised rat brain 31P MRS is a technically
challenging method and was used in the present study
to measure the tissue energy status specifically within
the area of IL-1β microinjection, minimising contamin-
ation of signal from surrounding non-injected tissue.
However, this approach has sensitivity limitations. The
dimensions of the 31P MRS voxel must be sufficiently
large for signal detection within a reasonable time acqui-
sition (in this case, 1 h). In the present study, the mean
peak height for PCr within the left and right cerebral
hemispheres for 3 control animals was 85 mm, and the
a
b
Fig. 4 The 31P MRS-detectable energy status of brain parenchyma
following IL-1β challenge. a Histogram showing the mean PCr to
γATP ratio (error bars indicate a 1 SD) within the ipsilateral and
contralateral striatum of IL-1β-injected (1 ng/μl) animals (n = 4) and
the ipsilateral striatum of vehicle- (saline) injected animals (n = 3) at
6 h. b Histogram showing the mean PCr to γATP ratio (error bars
indicate a 1 SD) within the ipsilateral and contralateral striatum of
IL-1β-injected (100 ng/μl) animals and the ipsilateral striatum of
vehicle- (saline) injected animals. 31P MRS data was not obtained for
the contralateral hemisphere at 6 h as this would have prolonged
the extensive (10 h) protocol on day 1 of imaging by a further 1.5 h.
Maintaining the animal under anaesthesia for long periods risks
death and changes in energy metabolism were not expected to be
observed in the contralateral hemisphere at this time point. IL-1
β-injected animals: n = 6 at 2.5 h, n = 5 at 6 h, n = 6 at 24 h, n = 4 at
72 h for the ipsilateral hemisphere and n = 5 at 2.5 h, n = 4 at 24 h
and n = 5 at 72 h for the contralateral hemisphere. Vehicle- (saline)
injected animals: n = 3 at each time point
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standard deviation 19 mm. Thus, within the limits of
sensitivity of this protocol, a minimal reduction of ap-
proximately 25 % in PCr is required to detect a change
in the PCr to γATP ratio.
One should consider how large a reduction in the PCr
to γATP ratio might be required to constitute energy
failure with confidence. In cerebral ischaemia in the rat,
in vivo PCr and ATP levels measured by 31P MRS have
been shown to decrease in parallel [26], in which case
one would not be able to detect an overall change in the
the PCr to γATP ratio. However, these observations
were based on extreme ends of the spectrum where the
metabolites were either nearing control values or were
extremely compromised [27–29]. Moderate ischaemic
challenges where 31P MRS-detectable PCr is reduced
but ATP is maintained have demonstrated that PCr
must decrease to 40 ± 26 % before ATP loss occurs [30].
When PCr is above 25 % of control value, ATP loss is
one-third that of PCr whereas below 25 % of control
PCr value, ATP loss supersedes that of PCr [30].
A better estimate of the sensitivity of the 31P MRS
protocol may be provided by a power calculation. The
sample size required to detect a 25 % change in the PCr
to γATP ratio 24 h following 100 ng/μl IL-1β challenge,
the time point exhibiting the spatially greatest and sever-
est reduction in ADC, is n = 49. This is impractical given
the challenging nature and long duration of the 31P MRS
protocol, and reinforces the unlikelihood that IL-1β in-
duces energy failure in vivo. By comparison, in rat cere-
bral ischaemia, whilst PCr is above 25 % of control
value, ATP loss is one-third that of PCr [30], as ex-
plained earlier. If, on that basis, a power calculation is
performed to show how many animals are required to
demonstrate a 75 % change in the PCr to γATP ratio,
n = 5. Therefore, within the sensitivity limitations of
the 31P MRS protocol, it is likely that a change in the
PCr to γATP ratio would only be detectable if the
metabolic impact was severe enough, which does not
appear to be the case following IL-1β challenge.
It is important to address the correlation between ADC
reduction and energy failure using in vivo models. In the
classic middle cerebral artery occlusion (MCAO) model of
brain ischaemia, energy failure perturbs ionic gradients in-
ducing cell oedema and reducing the extracellular space,
which depresses the ADC to 60–70 % of the original value
by 7 h [6, 31–33]. The association between ADC changes
and metabolic failure following MCAO has been proven
by anatomic mapping of regions of depressed ADC on
MRI with areas of acidosis, lactate accumulation [34] and
ATP loss, assessed using bioluminescence imaging on fro-
zen tissue [6]. One may conclude that a decrease in ADC
of approximately 40 % of its control value or the value in
the non-injected contralateral hemisphere constitutes en-
ergy failure in MCAO.
The same reasoning cannot be translated to other
non-ischaemic examples of ADC reduction in vivo. For
example, an excitotoxic NMDA challenge in the rat
brain induces a comparable ~ 40 % reduction in ADC,
which affects almost the entire injected hemisphere,
without tissue energy failure as assessed by 31P MRS
[14]. Injection of the excitotoxin, ouabain, into the rat
brain produces an approximate 40 % drop in ADC, al-
beit within a smaller sized lesion but without 31P MRS-
detectable metabolic failure [15]. Interestingly, brain
ADC reductions of ~ 18 % have been reported in an ex-
perimental model of status epilepticus, which did not
correlate with energy failure [16]. Thus, given our
present incomplete understanding of the mechanisms of
in vivo ADC reduction, it is not possible to make a dir-
ect association between magnitude of ADC reduction
and prediction of tissue energy failure in models other
than MCAO.
Partial volume effects are significant with respect to
both ADC and 31P MRS measurements. Following IL-1β
challenge, the partial volume effects on ADC measure-
ment have been demonstrated by comparing the ROI
analysis with the 31P MRS voxel analysis (Fig. 1b and d,
respectively). In Fig. 1b, the ADC at 24 h is reduced
within the injected hemisphere to ~ 90 % of the value in
the contralateral hemisphere. In Fig. 1d, the ADC meas-
urement within the confines of the 31P MRS voxel de-
tects an ADC reduction to 95 % of the value in the
contralateral hemisphere, thus halving the magnitude.
IL-1β diffusibility may appear unrestricted since ADC
changes were observed throughout the cerebral hemi-
sphere, particularly at 24 h, however, it seems that only
50 % of the parenchyma contained within the 31P MRS
voxel was affected by tissue water diffusion changes,
which would be expected to affect the sensitivity of 31P
MRS-detectable changes. However, as discussed earlier,
one cannot draw a direct correlation between magnitude
of ADC reduction and energy failure in non-ischaemic
challenges.
It is of note that astrocytes are the only brain cell-type
to exhibit a glycogen reserve, utilised during ischaemia
to preserve neuronal viability [35]. Interestingly, challen-
ging dissociated primary neuronal or astrocytic cell cul-
tures with IL-1β induces astrocytic utilisation of their
endogenous glycogen reserve whilst neuronal metabol-
ism is unaltered [36, 37]. Hence, an IL-1β challenge in
vivo may not alter the overall PCr to γATP ratio of brain
parenchyma.
The present study has shown that the ADC reduction
cannot be confidently attributed to depleted ATP levels,
as measured by 31P MRS. This finding has important im-
plications for the interpretation of ADC changes in the
brain because it occurs under metabolic conditions dis-
tinct from those concerning classic cerebral ischaemia,
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as is the case with rodent models of excitotoxic injury
[14, 15] and status epilepticus [16]. There are clear dif-
ferences in the consequences of an ischaemic, excito-
toxic or IL-1β-induced challenge for neurons. Ischaemic
or excitotoxic challenge induces neuronal cell death
[14, 15] whereas an intrastriatal IL-1β microinjection is
not neurotoxic [12, 13]. Therefore, any mechanistic ex-
planation for reduced ADC following IL-1β challenge is
likely to be different compared to that following excito-
toxic injury or ischaemia.
An improved understanding of the mechanisms under-
lying brain ADC changes in non-ischaemic challenge
and a closer examination of non-ischaemic in vivo
models of ADC reduction are warranted as this may fa-
cilitate an improved understanding of brain pathophysi-
ology observed non-invasively by routine ADC MRI.
This is particularly pertinent at the present time as IL-
1β appears to be a key player in the pathogenesis of neu-
rodegenerative diseases such as Alzheimer’s Disease and
Parkinson’s Disease [for reviews, see 1, 2]. There is great
interest in MR examination of these diseases clinically
and pre-clinically, particularly with respect to tissue
water diffusion measurements [38–40]. In order to inter-
pret the MR results effectively, it would be useful to have
an improved understanding of the contribution of the
IL-1β-induced component of the pathology to the brain
tissue water diffusion signal.
Conclusions
This is the first reported 31P MRS investigation of the
energetic response of brain parenchyma to an intrastria-
tal IL-1β challenge in vivo. Energy status, as defined by
the PCr to γATP ratio, remained unaltered within the
limits of localised 31P MRS detection, despite a chronic-
ally reduced ADC classically associated with energy fail-
ure in acute cerebral ischaemia. The negative finding of
no change in this energetic parameter is significant be-
cause it has been an unaddressed question in the field
for over a decade. Previous works investigating BBB
breakdown [3] and microglial activation [12] have also
failed to account for the IL-1β-induced chronic reduc-
tion in ADC. However, it is only by investigation of these
parameters that one may exclude them as causal factors.
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